Ask AI

EHA 2026

 
Virtual Simulcast
 
In-Person
 
Free CME/CE Credits

Summer Hematology 2026

Join us in Stockholm during EHA 2026 for 3 dynamic, expert-led symposia exploring the rapidly evolving landscape of hematologic malignancies. These sessions will spotlight frontline innovation in diffuse large B-cell lymphoma, including emerging BTK inhibitor–based strategies; novel approaches targeting protein degradation pathways in relapsed/refractory multiple myeloma; and the expanding role of bispecific antibodies in myeloma care. Each symposium offers complimentary CME, food, and beverages.

Attendance is open to registered EHA 2026 participants only.

 

Dates
Varies per event

 

Time
8:00 AM - 9:30 AM CET
Timezone Converter ›

 

Location
Stockholmsmässan
Massvagen 1
125 30 Alvsjö, Sweden

Event Schedule

June

12

2026

7:30 AM - 9:30 AM Central European Time (CET)

In-person

8:00 AM - 9:30 AM Central European Time (CET)

Virtual

June

13

2026

Claim Credit

To claim credit, click the link below, complete the evaluation, and you'll be given access to your certificate.

June 12 June 12 June 13

Featured Faculty

Faculty

Elizabeth Budde, MD, PhD

  • Associate Professor
  • Department of Hematology & HCT
  • City of Hope National Medical Center
  • Duarte, California
Faculty

Sagar Lonial, MD, FACP. FASCO

  • Chair and Professor
  • Department of Hematology and Medical Oncology
  • Anne and Bernard Gray Family Chair in Cancer
  • Chief Medical Officer
  • Winship Cancer Institute
  • Emory University School of Medicine
  • Atlanta, Georgia
Faculty

Gilles Salles, MD, PhD

  • Service Chief, Lymphoma Service
  • Steven Greenberg Chair
  • Memorial Sloan Kettering Cancer Center
  • Weill Cornell University
  • New York, New York
Faculty

Fredrik Schjesvold, MD, PhD

  • Head of Oslo Myeloma Center
  • Department of Hematology
  • Oslo University Hospital
  • Oslo, Norway
Faculty

Niels Van de Donk, MD, PhD

  • Professor of Hematology
  • Amsterdam UMC, Vrije Universiteit Amsterdam
  • Department of Hematology, Cancer Center Amsterdam
  • Amsterdam, The Netherlands
Faculty

Pier Luigi Zinzani, MD, PhD

  • Professor of Hematology
  • Alma Mater Studiorum-University of Bologna
  • Head, “Seràgnoli” Institute of Hematology
  • IRCCS Azienda Ospedaliero-Universitaria di Bologna
  • Department of Medical and Surgical Sciences
  • Bologna University School of Medicine
  • Bologna, Italy

Accreditation

Optimizing Frontline Treatment of DLBCL: An Expert Roundtable on the Emerging Role of BTK Inhibitor–Based Therapies

JOINT ACCREDITATION INTERPROFESSIONAL CONTINUING EDUCATION

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Passport

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.

Disclosure of Conflicts of Interest

Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Accreditation

Novel Approaches in Relapsed/Refractory Multiple Myeloma: Expert Perspectives on Emerging Data and Ongoing Trials

JOINT ACCREDITATION INTERPROFESSIONAL CONTINUING EDUCATION

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Passport

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.

Disclosure of Conflicts of Interest

Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Stockholmsmässan

Massvagen 1
125 30 Alvsjö, Sweden

Optimizing Frontline Treatment of DLBCL: An Expert Roundtable on the Emerging Role of BTK Inhibitor–Based Therapies
Provided by Clinical Care Options, LLC dba Decera Clinical Education
Supported by an educational grant from AstraZeneca.

Novel Approaches in Relapsed/Refractory Multiple Myeloma: Expert Perspectives on Emerging Data and Ongoing Trials
Provided by Clinical Care Options, LLC dba Decera Clinical Education
Supported by an educational grant from Bristol Myers Squibb.